Methsuximide-d5
Methsuximide-d5 is the deuterated-labeled Methsuximide (HY-B1376). Methsuximide (Mesuximide) is an orally active succinimide-derived antiepileptic agent. Methsuximide interacts with cytochrome P-450, increases the level of hepatic microsomal cytochrome P-450, and inhibits or competes with the cytochrome P-450 CYP 2C9/10 subtype. Methsuximide can be used in epilepsy-related research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1189980-63-9
- Fòrmula: C12H8D5NO2
- Peso molecular:208.27
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
In Vitro
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Aplicación
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
No. CAS 1189980-63-9
-
Unlabeled CAS 77-41-8
-
Peso molecular 208.27
-
Fòrmula C12H8D5NO2
-
SMILES
CC1(C(=O)N(C)C(=O)C1)C2=C(C(=C(C(=C2[2H])[2H])[2H])[2H])[2H]
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Orton TC, et al. Effect in rats of subacute administration of ethosuximide, methsuximide and phensuximide on hepatic microsomal enzymes and porphyrin turnover. Biochem Pharmacol. 1972 Aug 15;21(16):2253-61. [Content Brief]
[2]. CHEN G, et al. Anticonvulsant activity and toxicity of phensuximide, methsuximide and ethosuximide. Epilepsia. 1963 Mar;4:66-76. [Content Brief]
[3]. Sigler M, et al. Effective and safe but forgotten: methsuximide in intractable epilepsies in childhood. Seizure. 2001 Mar;10(2):120-4. [Content Brief]
[4]. Besag FM, et al. Methsuximide lowers lamotrigine blood levels: A pharmacokinetic antiepileptic drug interaction. Epilepsia. 2000 May;41(5):624-7. [Content Brief]
[5]. Dobrinska MR, et al. Pharmacokinetics of methsuximide and a major metabolite in dogs. Journal of pharmaceutical sciences. 1977 May;66(5):688-92. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Methsuximide-d5 Related Classifications
HY-132399S Related Classifications
Powered by Bioz
Keywords
- Methsuximide-d5
- 1189980-63-9
- Isotope-Labeled Compounds
- Cytochrome P450
- CYPs
- pentylenetetrazol-induced clonic seizures
- Sprague-Dawley rats
- CFHB Wistar rat liver microsomes
- Macaca rhesus monkeys
- cytochrome P-450
- chick embryo liver
- Webster strain mice
- electroshock-induced tonic extensor seizures
- CYP 2C9/10 isoform
- δ-aminolaevulinic acid synthetase
- Inhibitor
- inhibitor
- inhibit